Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

Abstract After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment strategy is commonplace in modern clinical practi...

Descripció completa

Dades bibliogràfiques

Autors principals:	Nicholas Mai, Carlos H. dos Anjos, Pedram Razavi, Anton Safonov, Sujata Patil, Yuan Chen, Joshua Z. Drago, Shanu Modi, Jacqueline F. Bromberg, Chau T. Dang, Dazhi Liu, Larry Norton, Mark Robson, Sarat Chandarlapaty, Komal Jhaveri
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2024-10-01
Col·lecció:	npj Breast Cancer
Accés en línia:	https://doi.org/10.1038/s41523-024-00699-3
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!